Candel Therapeutics (CADL) EBIT (2020 - 2025)

Candel Therapeutics has disclosed EBIT across 6 years of filings, most recently posting -$15.8 million for Q4 2025.

• EBIT for Q4 2025 came in at -$15.8 million, down 93.49% year-over-year; the trailing twelve-month figure through Dec 2025 was -$48.3 million (down 44.63% YoY), and the FY2025 annual result was -$48.3 million, down 44.63% from the prior year.
• EBIT came in at -$15.8 million for Q4 2025 at Candel Therapeutics, down from -$13.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$4.7 million in Q1 2021 to a low of -$15.8 million in Q4 2025.
• The 5-year median for EBIT is -$8.8 million (2022), against an average of -$9.0 million.
• Across the five-year window, EBIT plunged 192.07% in 2021 and advanced 21.1% in 2024, its largest moves.
• Candel Therapeutics' EBIT stood at -$7.7 million in 2021, then dropped by 4.66% to -$8.1 million in 2022, then retreated by 27.37% to -$10.3 million in 2023, then grew by 21.1% to -$8.1 million in 2024, then tumbled by 93.49% to -$15.8 million in 2025.
• The last three EBIT figures came in at -$15.8 million (Q4 2025), -$13.2 million (Q3 2025), and -$11.2 million (Q2 2025), per Business Quant data.